Boothbay Fund Management’s Aerie Pharmaceuticals AERI Stock Holding History

Boothbay Fund Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-40,600	Closed	-$614K	–	2755
2022 Q3	$614K	Buy	+40,600	New	+$472K	0.02%	1118
2020 Q1	–	Sell	-20,000	Closed	-$483K	–	1148
2019 Q4	$483K	Buy	20,000 +7,451	+59%	+$154K	0.04%	499
2019 Q3	$241K	Buy	+12,549	New	+$288K	0.02%	619
2018 Q4	–	Sell	-5,000	Closed	-$308K	–	970
2018 Q3	$308K	Buy	+5,000	New	+$321K	0.03%	497
2017 Q3	–	Sell	-7,965	Closed	-$419K	–	819
2017 Q2	$419K	Buy	+7,965	New	+$371K	0.09%	298

Boothbay Fund Management's AERI Position: Q4 2022 in Review

Boothbay Fund Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 40,600 shares — an estimated $614K sold.

Boothbay Fund Management first reported a position in AERI in Q2 2017 and held it in 5 quarters. The position peaked at $614K in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Boothbay Fund Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Boothbay Fund Management sold 40,600 Aerie Pharmaceuticals shares in Q4 2022, an estimated $614K.
Boothbay Fund Management first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 5 quarters.
Boothbay Fund Management's Aerie Pharmaceuticals position peaked at $614K in Q3 2022.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.